Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
27.56
-0.50 (-1.78%)
Dec 19, 2025, 12:25 PM EST - Market open
Fulgent Genetics Revenue
Fulgent Genetics had revenue of $84.07M in the quarter ending September 30, 2025, with 17.18% growth. This brings the company's revenue in the last twelve months to $315.55M, up 13.60% year-over-year. In the year 2024, Fulgent Genetics had annual revenue of $283.47M, down -1.99%.
Revenue (ttm)
$315.55M
Revenue Growth
+13.60%
P/S Ratio
2.73
Revenue / Employee
$240,327
Employees
1,313
Market Cap
851.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
| Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
| Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
| Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
| Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
| Dec 31, 2019 | 32.53M | 11.18M | 52.35% |
| Dec 31, 2018 | 21.35M | 2.62M | 13.99% |
| Dec 31, 2017 | 18.73M | 454.00K | 2.48% |
| Dec 31, 2016 | 18.28M | 8.70M | 90.85% |
| Dec 31, 2015 | 9.58M | 8.30M | 649.30% |
| Dec 31, 2014 | 1.28M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
FLGT News
- 5 weeks ago - Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 5 weeks ago - Fulgent to Participate in Upcoming Conferences - Business Wire
- 5 weeks ago - Fulgent Genetics, Inc. (FLGT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Fulgent Reports Third Quarter 2025 Financial Results - Business Wire
- 2 months ago - Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference - Business Wire
- 2 months ago - Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025 - Business Wire
- 3 months ago - Fulgent Genetics: Core Growth Re-Acceleration And Gross Margin Expansion Are On Track (Reiterate Buy) - Seeking Alpha
- 5 months ago - Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript - Seeking Alpha